Literature DB >> 8433531

[Diagnosis of predictive state of disseminated intravascular coagulation].

K Yamamoto1, H Saito.   

Abstract

The early stage of the state in which coagulation or fibrinolytic pathway is activated has been difficult to be estimated. Recently, it has become possible to detect an early stage of DIC (pre-DIC) due to the development of highly sensitive methods which quantitate so called "molecular markers". Molecular markers can be classified into three groups: 1) activation fragments of coagulation proteins (e.g. F1+2); 2) protease and its inhibitor complex (e.g. TAT, IXa-AT-III, Xa-AT-III and PIC); 3) degradation products (e.g. FPA, FPB beta, SFMC and D-dimer). Among them, F1+2, TAT, FPA and SFMC reflect in vivo thrombin generation, while PIC, FPB beta and D-dimer reflect in vivo plasmin generation. IXa-AT-III and Xa-AT-III may be useful markers to detect hypercoagulable states in an earlier stage of underlying various disorders. Measurement of circulating levels of the zymogens and protease inhibitors is unable to detect small changes caused by low grade DIC or localized thrombotic events. Monitoring plasma levels of molecular markers, however, gives us more specific and accurate information regarding the onset and time course of hypercoagulable states and enable us to diagnose DIC at an early stage and to evaluate the effect of treatment for patients with DIC, specifically.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433531

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  2 in total

1.  The evaluation of coagulation profiles in calves with suspected septic shock.

Authors:  K Irmak; I Sen; R Cöl; F M Birdane; H Güzelbektes; T Civelek; A Yilmaz; K Turgut
Journal:  Vet Res Commun       Date:  2006-07       Impact factor: 2.459

2.  Thrombin-antithrombin complex measurement using a point-of-care testing device for diagnosis of disseminated intravascular coagulation in dogs.

Authors:  Kenji Rimpo; Aki Tanaka; Masayasu Ukai; Yuichi Ishikawa; Miyuki Hirabayashi; Toshihiro Shoyama
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.